Objective: Reprogramming of fibroblasts into induced cardiomyocytes represents a potential new therapy for heart failure. We hypothesized that inactivation of p63, a p53 gene family member, may help overcome human cell resistance to reprogramming.
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Silencing p63 in cardiac fibroblasts transdifferentiates cardiomyocyte-like cells.
Central Message
Downregulation of p63 facilitates cardiac cellular transdifferentiation and may help overcome the resistance of human cells to reprogramming.
Perspective
Recent success reprogramming rodent cardiac cells has been tempered by the relative human cell resistance to reprogramming with currently defined transdifferentiation factors, perhaps due to more rigorous epigenetic constraints in higher-order species. Downregulation of antiplasticity genes such as p63 may enhance cellular plasticity and thereby improve reprogramming efficiency in human cells.
See Editorial Commentary page 566.
Nearly 5 million Americans can be expected to develop advanced congestive heart failure, typically characterized by the replacement of normal contractile cardiomyocytes with fibroblasts and scar tissue after 1 or more episodes of myocardial infarction. 1, 2 Highly invasive surgical procedures such as heart transplant or mechanical circulatory support implantation represent the limited treatment options available for patients with end-stage heart failure, which has traditionally been considered to be an otherwise highly lethal and irreversible condition.
Recently, the novel strategy of in situ transdifferentiation of fibroblasts into induced cardiomyocytes (iCMs) via genetic reprogramming has offered an exciting and promising new solution for the treatment of heart failure. 4, 5 Inspired by the discovery that adult somatic cells could be dedifferentiated into induced pluripotent stem (iPS) cells, the concept of cellular transdifferentiation capitalized on the recognition that specific sets of transcription factors and other cellular reprogramming agents could convert one cell type into another without passing through a pluripotent, fully dedifferentiated iPS stage. [4] [5] [6] More specifically, the cardiac-differentiating transcription factors Gata4, Mef2c, and Tbx5 were the first to be shown to reprogram cardiac fibroblasts into cardiomyocytes, following which a wide variety of other reprogramming cocktails were shown to induce iCM generation and improvements in postinfarct ventricular function in vivo. 5, [7] [8] [9] Despite these encouraging findings, it was soon discovered that human cardiac fibroblasts were resistant to reprogramming compared with rodent cells, likely on the basis of more rigorous epigenetic controls imposed on gene activation in higher-order species. 8, [10] [11] [12] [13] Expanded cocktails of reprogramming factors were found to overcome this resistance, but the administration of complex mixtures of reprogramming factors represents a formidable barrier to human cellular reprogramming, especially in potential clinical therapeutic applications. [14] [15] [16] In the context of the intriguing observation that tumor suppressor genes such as p53, p63, p21, p19, and p16 inhibit iPS cell reprogramming, [17] [18] [19] [20] [21] we speculated that such genes may also impede the transdifferentiation of fibroblasts into cardiomyocytes by acting as ''antiplasticity genes.'' Given the prohibitive oncogenic risk associated with downregulation of p53, we elected to narrow our focus on strategies for enhancing human cardiac cellular transdifferentiation to the downregulation of p63, a member of the p53 gene family with a reduced oncogenic profile compared with p53.
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METHODS
Cell Culture
Previously characterized p53 knockout ( À/À ) murine embryonic fibroblasts (MEFs) were gifted from Dr Michelle Barton, MD Anderson Cancer Center. 25 p63 Knockout (
) MEFs were constructed with a deletion of the DNA binding domain for the DN-p63 and TA-p63 isoforms at exons 6 to 8 of the p63 gene. 21, 26 A stable p63 knockdown MEF cell line was established after p63 lentiviral short hairpin RNA (shRNA) transduction (GE Healthcare Dharmacon, Lafayette, Colo; Clone ID: V3LMM_508694), followed by puromycin selection (1 mg/mL) for 5 to 7 days. All MEFs were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 15% fetal bovine serum (FBS), 1% nonessential amino acids (Cat. No. 11140050; Gibco, Gaithersburg, Md), and 1% penicillin/streptomycin.
Primary adult mouse cardiac fibroblasts were generated from inducible knockout mice (p63
, strain C57BL/6, age 8-10 weeks), which have Creactivated loxP sequences flanking the DNp63 gene ( Figure E1) . 21, 27 These fibroblasts were isolated via a gentleMACS Dissociator (Miltenyi Biotec, Gladbach, Germany) under a protocol approved by the Baylor College of Medicine (BCM) Institutional Animal Care and Use Committee, following which they were cultured on 0.1% gelatin-coated flasks in Iscove's Modified Dulbecco's Medium (Thermo Fisher Scientific, Waltham, Mass) culture medium supplemented with 20% FBS, 1% penicillin/ streptomycin.
Adult human cardiac fibroblasts were harvested from patients undergoing heart transplant or mechanical circulatory support procedures for heart failure (BCM Institutional Review Board approval H-33421; approval date September 25, 2017) . The same p63 shRNA lentivirus described previously was used to induce p63 knockdown in these cells. These cells were maintained in FGM Fibroblast Growth Media (CC-4526; Lonza, Walkersville, Md) after infection as previously described. 12 
Vectors
Lentiviral vectors were prepared from a doublet plasmid encoding Hand2-Myocardin (HM; System Biosciences, Palo Alto, Calif). 28 Adenovirus (Ad) control vectors encoding green fluorescent protein (GFP), or Ad vectors encoding Cre and GFP, were obtained from the BCM Vector Development Lab. Viral transduction was performed respectively with multiplicity of infection of 20 (for lentiviruses) or 200 (for Ad) using transfection reagent polybrene (8 mg/mL; Millipore, Burlington, Mass), based on our experience that these dosages provide the greatest level of transgene expression. After 24 to 48 hours of transfection, media were replaced with reprogramming media consisting of DMEM and M199 supplemented with 10% FBS, 1% nonessential amino acids, and 1% penicillin/streptomycin. All cells were maintained for up to 3 weeks before analysis by flow cytometry, quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), and immunofluorescence (IF). Co-culture and measurements of contractility and calcium transient. Adult murine p63
Cell Characterization Assays
fl/fl cardiac fibroblasts were seeded onto a 6-well plate coated with 0.1% gelatin at a density of 150,000/well. Two days later, the cells were infected with Ad-GFP control or Ad-Cre-GFP, with or without lentivirus encoding HM, and iCM media were applied the next day. 12 One week later, the cells were harvested and replated at a ratio of 1:4 onto cultures of primary neonatal rat cardiomyocytes. 12 These had been isolated with the Miltenyi Biotec GentleMACS
Dissociator and seeded at a density of 50,000 cells/well onto 0.1% gelatin-coated 12-well plates in DMEM, M199, 4% horse serum, and preconditioned medium obtained from neonatal rat cardiomyocytes. 7 Cocultured cells were incubated for a total of 7 weeks.
Cell shortening and Ca 2þ transients. Myocytes were fieldstimulated at room temperature to contract by using a Grass S5 stimulator through platinum electrodes placed alongside the bath (1 Hz, bipolar pulses with voltages 50% above myocyte voltage threshold). 29 Cells from random fields were videotaped, and motion was digitized on a computer to assess contractility. For Ca 2þ signal measurements, cells were loaded with 1.8 mM Ca 2þ and 2 mmol/L Fura-2/AM (Life Technologies, Carlsbad, Calif) for 1 hour at room temperature, washed, and incubated for an additional 1 hour to allow de-esterification of the dye, and then alternately excited at 340 and 380 nm by using a Delta Scan dual-beam spectrophotofluorometer (Photon Technology International Inc, Birmingham, NJ). Ca 2þ transients were expressed as the 340/380 nm ratios of the resulting 510-nm emissions. Data were analyzed with Felix software (Photon Technology International Inc).
Cell proliferation and soft agar oncogenicity assays. To assess cell proliferation, 1 3 10 4 cells were seeded onto a 24-well plate, and the total number of viable cells was counted daily for 1 week. Adherent cells were detached with trypsin 0.05%, stained with trypan blue, and counted with a Bio-Rad Automated Cell Counter. Soft agar assays were performed as previously described. 30 Briefly, 10,000 cells were seeded in a 6-well plate containing soft agar, and images were taken 2 weeks after culture (4003).
Statistical Analysis
Data are represented as mean values AE standard deviation, unless otherwise indicated. Differences between groups were examined for statistical significance by using the Student t test or analysis of variance. We tested the assumption of normality in each group using the Shapiro-Wilk test and Kolmogorov-Smirnov test. We determined that our data were normally distributed in all groups. Then, we applied post-hoc testing after analysis of variance and adjusted our P values with the Bonferroni method. A P value < .05 was considered to indicate significance. 
RESULTS
Cardiomyocyte Marker Expression Induced by Downregulation of p63
To determine whether the p53 gene family could be modulated to enhance cellular reprogramming, we first analyzed cTnT expression in cultures of p53 À/À and wild-type (WT) MEFs. Flow cytometry demonstrated that cTnT was expressed in 12% AE 0.3% versus 1.2% AE 0.6% of these cells, respectively (P < .05). We next demonstrated that significantly increased proportions of p63 À/À MEFs also expressed cTnT versus WT controls (38% AE 11% vs 0.9% AE 0.9% of cells, P < .05; Figure 1, A and B) .
When p63 À/À MEFs were treated with HM, the percentage of cells expressing cTnT increased to 74% AE 3%, whereas HM treatment did not induce cTnT expression in WT MEFs. p63
À/À MEFs also demonstrated increased expression of the cardiac-transdifferentiation genes Gata4, Mef2c and Tbx5 (Figure 1, C) , suggesting a potential mechanism of action underlying the cardiodifferentiation of cells with p63 deletion.
To assess whether (shRNA-mediated) p63 knockdown could also induce cTnT þ cardiomyocyte-like cells, we first confirmed that p63 shRNA-treated MEFs demonstrated an appropriate level of reduction of p63 microRNA (mRNA) expression (Figure 2, A) . Following this validation, we observed that p63 knockdown in MEFs induced approximately a 20-fold increase in cTnT mRNA expression and a 3-to 5-fold increase in the mRNA levels of Gata4, Mef2c, and Tbx5 (Figure 2, B) , consistent with our observations in p63 À/À MEFs.
Adult p63 À/À Cardiac Fibroblasts Demonstrated Cardiomyocyte-Like Features
Having determined that p63 silencing could enhance the transdifferentiation of embryonic cells into cardiomyocytelike cells, we next asked whether p63 downregulation would induce similar changes in adult cells. Adult murine p63 fl/fl cardiac fibroblasts were accordingly treated with Ad encoding Cre recombinase (Ad-Cre) or a negative control vector (Ad-GFP). As expected, Ad-Cre administration substantially decreased p63 expression, as verified by qRT-PCR (Figure 3, A) . Depletion of p63 in these cells resulted in a 200-fold increase in the expression levels of cTnT (Figure 3, B) . IF staining likewise revealed intracellular expression of the cardiac-specific protein markers sarcomeric a-actinin and cTnT in these p63 À/À cells but not in cells treated HM alone or in Ad-GFP-treated control cells ( Figure 3, C and D) .
To demonstrate that these changes in molecular phenotype corresponded to relevant functional changes in cells with induced p63 silencing, we performed calcium transient and cellular contraction assays on p63 À/À adult murine cardiac fibroblasts co-cultured with neonatal rat cardiomyocytes, as recommended by previous investigators as a means of inducing iCM contractility in vitro. 10, 12 In this analysis, approximately 2% of the p63 À/À cardiac fibroblasts treated with HM demonstrated contractions in response to electrical field stimulation, whereas no contractions were observed in cells treated with Ad-GFP or Ad-Cre alone (Figure 4 , A, and Videos 1-3). HMtreated p63 À/À cardiac fibroblasts likewise demonstrated calcium transients and cell shortening corresponding to their visual contraction (Figure 4, B) .
Several observations support the conclusion that the cells observed to be contracting in these functional studies were the (HM-treated) p63 À/À cardiac fibroblasts and rule out the possibility that these findings could represent the artifact of neonatal cardiomyocyte contractions in this preparation. First, cell contractility was not observed when neonatal cardiomyocytes were cultured without the addition of p63 fl/fl fibroblasts, consistent with the known loss of this native cardiomyocyte phenotype after the 7 weeks in culture at which time point our contractility studies were undertaken. 31 Second, contractility was also not seen in wells containing cardiomyocytes co-cultured with Ad-GFPtreated p63 fl/fl cardiac fibroblasts (ie, WT control cells), or with (Ad-Cre-treated) p63 À/À cells without HM treatment (Figure 4 , A, and Videos 1-3). Third, given that contractions were detected only in GFP þ (ie, Ad-infected) cells, and that (GFP-labeling) Ad was only administered to p63 fl/fl fibroblasts before their introduction into co-culture, it is unlikely that untreated neonatal cardiomyocytes could be mistakenly analyzed as (GFP-labeled) p63 À/À cardiac fibroblasts.
Cardiomyocyte Marker Expression in Adult Human Cells With p63 Knockdown
On the basis of our analysis of the effects of p63 silencing in embryonic and adult rodent fibroblasts, we analyzed the effects of p63 knockdown in (primary culture) adult human cardiac fibroblasts obtained from patients with heart failure. In these studies, p63 knockdown human cardiac fibroblasts demonstrated up to a 30-fold increase in cTnT mRNA expression levels compared with untreated human cardiac fibroblasts ( Figure 5 ).
Minimal Neoplastic Transformation With p63 Knockout
We also evaluated whether p63 silencing could potentially induce neoplastic transformation, given its homology to p53, using 2 standard assays for this parameter: colony formation in soft agar and in vitro proliferation assays. [22] [23] [24] p63 À/À MEFs demonstrated negligibly increased replication rates compared with WT MEFs, whereas p53 À/À MEFs, used as a control comparator, demonstrated significantly increased replication rates (Figure 6, A) . Likewise, although p53 À/À MEFs grew into large colonies in soft agar cultures, a marker of oncogenicity, the p63 À/À MEFs produced smaller colonies that were comparable with those of WT cells (Figure 6, B) .
DISCUSSION
Given the now well-documented barriers to the reprogramming of human cells compared with that of lower-order species, we sought to enhance the susceptibility of cells to reprogramming as an alternative to the use of expanded reprogramming cocktail mixtures used by others to overcome this challenge. 8, [10] [11] [12] [13] [14] [15] [16] We were able to demonstrate that the transdifferentiation of both rodent and human fibroblasts into cardiomyocyte-like cells was enhanced by the downregulation of p63, a member of the cell senescence family of genes of which p53 is the prototype. This approach was stimulated by the observation that downregulation of either of these genes enhance iPS reprogramming, suggesting they serve as ''antiplasticity'' genes that may normally suppress excessive or promiscuous gene activation. [18] [19] [20] [21] [22] Given the large number of human neoplasms associated with p53 mutations, we elected to target p63, which has been associated with a far smaller human oncogenic profile than has p53.
23, 24 We did not explore the reprogramming effects of other p53 family members such as p73, which have not been described to have antiplasticity effects like p53 and p63. 24 Encouragingly, p63 downregulation appears to be even more effective than p53 downregulation in enhancing cellular reprogramming (Figure 1) , consistent with observations that p63 is a potent antiplasticity factor. 21 Likewise, p63 downregulation resulted in cTnT expression levels 4-fold greater than that which we have observed using optimized reprogramming cocktails on WT cells. 9, 12, 32 Given the apparent potency of p63 silencing, it is prudent to first ask whether p63 downregulation incurs the risk of neoplastic transformation, despite the lack of evidence of this risk in the clinical literature. 23, 24 Consistent with previous studies, encouragement can be derived from our observations of a lack of such oncogenicity effects with p63 versus p53 downregulation in soft agar and cell replication assays-the ''gold standards'' for in vitro neoplastic transformation. 23, 24, 33 Additional relevant safeguards may be found in the limited duration of p63 downregulation that is apparently needed to enhance reprogramming (as can be provided with Ad vectors), 28 and the ability to deliver p63 shRNA locally to cardiac tissues, which naturally have a very low baseline predilection to malignancy. It may also be possible to narrow therapy to a single isoform of p63 or to a downstream effector of p63, such as DCGR8. 21 Notwithstanding these assurances, more rigorous in vivo validation of these safety data will certainly be needed before clinical applications are considered.
Our findings of the potency of p63 silencing on cardiac fibroblast transdifferentiation is surprising, given that p63 has been previously associated primarily with epithelial development. 21, 23, 24 In this context, it is interesting to consider that the spontaneous differentiation of p63
MEFs into cardiomyocyte-like cells observed in our studies may represent a ''default'' differentiation pattern, consistent with the heart being the first organ formed in embryonic development. 34 In this paradigm, once p63 gene repression is released, cells revert to a predominant cardiomyocyte gene expression pathway, and the addition of additional cardio-differentiating genes like HM simply enhance this endogenous pathway. 7, 8, [10] [11] [12] The molecular mechanism underlying cellular cardiodifferentiation mediated by p63-silencing may be related to our observation of the upregulation of the cardiacreprogramming genes Gata4, Mef2c, and Tbx5 in p63-deficient cells (Figures 1 and 2) ; specifically, that p63 repression allows for the increased expression of these otherwise-repressed cardio-differentiating genes. The observation that exogenous Gata4, Mef2c, Tbx5 together with HM can substitute for p63 downregulation in inducing human cellular reprogramming is consistent with these data. [10] [11] [12] This premise is supported by our findings of effective cardiac reprogramming with p63 downregulation in adult human cardiac fibroblasts as well as embryonic and adult rodent cells. On the other hand, it is possible that p63 downregulation also activates genes, such as the Wnt and B-catenin signaling pathways, which have been shown to be modulated by p63 expression and facilitate cardiac cellular reprogramming. 13 Although we have not yet identified the specific epigenetic processes by which p63 downregulation leads to enhanced gene activation and cardiodifferentiation, one recently discovered pathway involves the complexing of p63 with histone deacetylases to induce chromatin condensation and the rendering of various gene promoter sites inaccessible to activator complexes. 35 Conceivably, release of p63 repression may thus allow access to these otherwise excessively repressed promoter sites in human cells. FIGURE 5 . Cardiomyocyte marker expression in adult human cells treated with shp63. A, qRT-PCR analysis showing decreased p63 mRNA expression levels in shp63-treated versus scrambled shRNA treated human cardiac fibroblasts, obtained from patients undergoing heart transplant or circulatory support implants, as detailed in the Methods (n ¼ 2). B, Human cardiac fibroblasts procured as described in the Methods demonstrating increased cTnT mRNA expression levels 7 days after treatment with shp63 as compared with cells treated with a scrambled shRNA control (Scr.). Gene expression was normalized to glyceraldehyde 3-phosphate dehydrogenase (n ¼ 2). mRNA, MicroRNA; cTnT, cardiac troponin T.
Taken together, the findings of the present study suggest that downregulation of p63 may be a safe and effective strategy for inducing human cardiac cellular reprogramming as a potential therapeutic strategy for the treatment of heart failure. This strategy seeks to overcome barriers to human cellular reprogramming by increasing target cell susceptibility to this process, as compared with present strategies that largely rely on adding a greater number of reprogramming factors to treatment cocktails. The latter may prove to be unduly complex and cumbersome for potential clinical application.
Study Limitations
Limitations of the current study include our lack of a more expansive analysis of factors other than HM that might optimally enhance cardiac reprogramming, an expanded analysis of additional potential mechanisms of action such as histone deacetylase repression or cellular apoptosis, and our use of a relatively limited, albeit previously validated panel of cardiomyocyte markers (ie, cTnT, a-actinin, and myosin heavy chain) to define a cardiomyocyte-like phenotype.
Furthermore, although we did demonstrate critically important physiologic cardiomyocyte markers (ie, calcium transients and cell contraction) in p63-downregulated cells, co-culture of these cells with neonatal cardiomyocytes was needed to induce this phenotype. This is consistent with the use of this requisite reprogramming methodology in other in vitro reprogramming studies, 12 presumably because of the need for an appropriate cardiac ''milieu'' to induce reprogramming, as suggested by greater efficacy of reprogramming effects observed in in vivo versus in vitro studies. [7] [8] [9] [10] [11] [12] The aforementioned considerations also apply to the relatively low efficiency of reprogrammed cells demonstrating a ''full'' (contractile) phenotype, which previous studies suggest might be more robust in the in vivo cardiac milieu. [7] [8] [9] [10] [11] [12] Finally, although our use of human cardiac fibroblasts is encouraging in terms of the ultimate clinical applicability of this proposed human cardiac reprogramming strategy, it must be recognized that the cell-culture process inherently selects out the ''healthier'' cells that can survive the explantation and in vitro culture propagation process. It is therefore not possible to definitively extrapolate these in vitro findings to potential results of in situ cell reprogramming that will ultimately require in vivo testing data that we now plan to perform. Mouse  GAPDH  TCACCACCATGGAGAAGGC  GCTAAGCAGTTGGTGGTGCA  p63  CTGGTATTTTTGTGTTATGGGCT  TGGCAAACAAAAATGGCTTA  cTnT  GTGTGCAGTCCCTGTTCAGA  CTTCTTCCTGTTCCTCCTCGT  Gata4  GGAAGACACCCCAATCTCG  CATGGCCCCACAATTGAC  Mef2c  TCTGCCCTCAGTCAGTTGG  CGTGGTGTGTTGTGGGTATC  Tbx5  CGAAGTGGGCACAGAGATG  CACCTTCACTTTGTAACTAGGAA   Human  GAPDH  CAACGACCACTTTGTCAAGC  GGTGGTCCAGGGGTCTTACT  Dnp63  GAAAACAATGCCCAGACTCAA  TGCGCGTGGTCTGTGTTA  cTnT  AGACGCCTCCAGGATCTGT  TCTTCAACAGCTGCTTCTTCC  Gata4  TTCCAGCAACTCCAGCAA  TCGCACTGACTGAGAACGTC  Mef2c  TGATCAGCAGGCAAAGATTG  TGGACACTGGGATGGAGACT  Tbx5  CCAGGAGCATAGCCAAATTTAC  AGGGCTTCTTATAGGGATGGTC  Hand2  GAAGACCGACGTGAAAGAGG  TTCTTGTCGTTGCTGCTCAC  Myocardin  AGGGCACAGGGTCTCCTC  GGAAGAATGGGGAGAGAAGC  MYH6  AAGAATGTGCATGAGCTGGA  GATCTTGCCCTCCTCGTG  MYH7  ACACCCTGACTAAGGCCAAA  ATGCGCACCTTCTTCTCTTG  Nkx2.5  AGTGTGCGTCTGCCTTTC  GTTGTCCGCCTCTGTCTTC  C-kit  GCTCTGCTTCTGTACTGCCA  GGGGATGGATTTGCTCTTT  Isl1 ACCTTGGAAAGTACTGAGCG GGTGTATCTGGAAGTTGAGAG GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; cTnT, cardiac troponin T.
FIGURE E1. Schematic diagram depicting p63 fl/fl inducible knockout mouse model. p63 fl/fl inducible knockout mice were generated using the Cre-loxP system, as described previously. 26 LoxP sequences, which recog- 565.e1 The Journal of Thoracic and Cardiovascular Surgery c August 2018
